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Summary The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell
carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34
patients with other types of lung cancer and 35 patients with benign diseases. To compare the results with
those obtained by the conventional competitive radioimmunoassay (RIA) using a polyclonal antibody, a new
immunoradiometric assay (IRMA) method was used which has recently been developed using two monoclonal
antibodies raised to different epitopes of TA-4. Both methods provided essentially the same results: the serum
TA-4 levels were high in patients with SCC of various organs when compared with those of healthy controls
and patients with other types of lung cancer or benign diseases. However, the positive ratios assessed as the
percentage of patients with elevated serum TA-4 levels were higher with the IRMA method than with the RIA
method in SCC of all organs, as much as 2-3 times higher in SCC of the larynx, tongue and pharynx. In
contrast, in patients with benign diseases or other types of lung cancer, there was no difference in the positive
ratios between the two methods. This was largely due to the improvement in sensitivity and accuracy of assay
with the new method, which resulted in a decrease in the normal value in healthy controls. It was concluded
that with the new IRMA method using monoclonal antibodies, the diagnostic detectability of serum TA-4 is
enhanced in SCC of all organs.
Since the initial report of Kato and Torigoe (1977), it has
been established that tumour-antigen 4 (TA-4), a protein
fraction purified from squamous cell carcinoma (SCC) tissue
of the uterine cervix, is a useful marker for uterine cervical
SCC (Kato et al., 1979, 1982, 1983, 1984; Maruo et al.,
1985). Previously, we measured serum TA-4 in patients with
SCC of various organs including the lung, oesophagus, max-
illary sinus and oral cavity and demonstrated that TA-4 is a
useful marker for SCC not only of the uterine cervix but also
of these organs, especially in evaluating therapeutic effects
and monitoring recurrence (Mino et al., 1988). In the
previous study, however, we also found that the serum TA-4
level and the positive ratio (the percentage of patients with
serum TA-4 levels higher than the normal range) were not so
high in the early stages of these diseases and even in the
advanced stages in SCC of the tongue, larynx and pharynx,
suggesting that its use in these cases was limited. This limita-
tion may be due to, in part at least, the sensitivity and
accuracy of the assay method used: the competitive conven-
tional radioimmunoassay (RIA) method using a polyclonal
antibody.
Recently, monoclonal antibodies for TA-4 were obtained
and an immunoradiometric sandwich assay (IRMA) method
using two monoclonal antibodies was developed (Dainabot
Co. Ltd, Tokyo, Japan) (Ikeda, 1987). Using the newly
developed IRMA method, in the present study, we measured
the serum TA-4 levels in healthy controls and in patients
with various types of diseases including SCC, and compared
the results with those obtained using the conventional RIA
method.
Materials and methods
Patients
Blood samples were obtained from 181 untreated patients
with SCC of various organs (71 lung, 16 oesophagus, 64 head
and neck, 24 uterine cervix and six skin), 34 patients with
other types of lung cancer (19 with adenocarcinoma, 15 with
small cell carcinoma), and 35 patients with benign diseases
(six lung, 13 thyroid, seven liver and nine kidney). In addi-
tion, 59 healthy volunteers (36 males and 23 females) served
as controls. All patients with carcinoma were classified ac-
cording to the tumour node metastasis (TNM) classification
of the Union Internationale contre le Cancer (UICC), and
the diagnosis was confirmed by histological examination in
all cases.
Assay
The serum TA-4 level was determined both by the new
IRMA method (SCC RIABEAD, Dainabot, Tokyo, Japan)
and by the conventional RIA method (SCC RIA kit,
Dainabot, Tokyo, Japan). The IRMA method is a sandwich
assay system consisting of two murine monoclonal antibodies
which recognise different epitopes (Ikeda, 1987). Briefly, one
of these antibodies was used to coat polystyrene beads and
the other was labelled with 125I. The assay procedure was as
follows. Each bead was incubated with 501tl of standard or
sample solution and 100 l I of the '251-labelled antibody solu-
tion. After gentle shaking for 3 h at room temperature, each
bead was washed with distilled water three times and the
radioactivity bound to the bead was counted. All standards
and samples were assayed in duplicate.
Results
Figure 1 shows a standard curve of TA-4 from the new
IRMA method using monoclonal antibodies. TA-4 could be
determined within a range from 0.3- 150 ng ml-' with an
average intra-assay deviation of 2.4% and interassay devia-
tion of 5.9%. On the other hand, using the conventional RIA
method, the serum TA-4 level of 0.6-150ngml-' could be
determined with an average intra-assay deviation of 6.2%
and interassay deviation of 7.3%. Thus, the new IRMA
method was superior in sensitivity and accuracy to the con-
ventional RIA method. In both assay systems, other tumour
antigens such as carcinoembryonic antigen (3-300ngml-')
and alpha-fetoprotein (40-320ngml-') did not cross-react.
Figure 2 shows the correlation between TA-4 values of 309
samples determined by the IRMA method and those deter-
mined by the RIA method. There was a highly significant
positive correlation (r = 0.98, P <0.001) and the slope of the
line was 1.05 within the range from 0.3 to 70ngml-'. The
insert in Figure 2 also shows a significant positive correlation
(r = 0.55, P <0.01) in the lower range of 0.3-2.5 ng ml-'
with samples obtained from 59 normal controls. However,
the slope of this line was 0.38, smaller than that in the range
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Figure 1 Immunoradiometric assay of TA-4 (X). A, CEA, car-
cinoebryonic antigen; X, AFP, alpha-fetoprotein.
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Figure 3 Serum TA-4 levels in norm,al controls and patients with
various diseases determined by the conventional RIA method.
Sq. C. Ca, squamous cell carcinoma; Adenoca, adenocarcinoma;
Small C. Ca, small cell carcinoma.
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Figure 2 Correlation between TA-4 values determined by the
new IRMA method and the conventional RIA method. n = 309;
Y= I.05X -0.48; r = 0.98; P <0.001.
of 0.3-70 ng ml-', indicating that in samples with lower
TA-4 levels, levels measured by the IRMA method were
lower than those measured by the RIA method. Thus in the
59 normal controls, the mean TA-4 serum level was
1.5 ± 0.53 ng ml-' by the RIA method and
0.97 ± 0.25 ng ml-' by the IRMA method. From these data,
the values of 2.6 ng ml-' for the RIA method and
1.4 ng ml-' for the IRMA method were adopted as the upper
limit of the normal range, and serum levels higher than these
values were considered 'positive'.
Serum TA-4 levels in various types of diseases estimated
by the two methods are shown in Figures 3 and 4 sum-
marised in Table I. The two methods gave essentially the
same results as follows. Serum TA-4 levels in patients with
SCC were high compared with those in patients with other
types of lung cancer or benign diseases, although they varied
considerably from organ to organ. However, there were some
differences between the data obtained by the two methods.
Serum TA-4 levels obtained by the IRMA method were
lower than those obtained by the RIA method not only in
normal controls but also in patients with SCC of almost all
organs, especially the larynx, oral cavity, tongue and pharynx
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Figure 4 Serum TA-4 levels in normal controls and patients with
various diseases determined by the IRMA method. Sq. C. Ca,
squamous cell carcinoma; Adenoca, adenocarcinoma; Small
C. Ca, Small cell carcinoma.
whose serum TA-4 levels were rather low. Moreover, the
positive ratio in the IRMA method was higher than that of
the RIA method in SCC of almost all organs, for example,
three and two times higher in SCC of the larynx, tongue and
pharynx (TableI). On the other hand, the positive ratio in
lung cancer other than SCC was nearly the same with the
two assay methods.
Table II shows serum TA-4 levels and positive ratios in
patients with SCC of the lung in relation to their clinical
stage. With both methods, there was a tendency for the
serum TA-4 level to increase with progression of the clinical
stage. However, in the earlier stages of I and II, the serum
TA-4 levels obtained by the IRMA method were lower than
those obtained by the RIA method. In all clinical stages
except stage I, the positive ratio obtained by the IRMA
method was higher than those obtained by the RIA method.
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Table I Serum TA-4 levels in normal controls and patients with lung cancer or squamous
cell carcinoma of various organs determined by the conventional RIA method and the new
IRMA method
Serum TA-4 (ng ml')
n Conventional RIA New IRMA
Normal controls 59 1.52 ± 0.53 (3%) 0.97 0.25 (3%)
Benign diseases 35 1.66± 1.21 (12%) 0.94± 0.97 (12%)
Lung cancer
Adenocarcinoma 19 1.99± 2.71 (11%) 1.48± 3.05 (11%)
Small cell ca. 15 2.89 4.17 (20%) 2.49 5.47 (20%)
Squamous cell carcinoma
Uterus 24 7.49 ± 7.65 (75%) 7.65 ± 8.71 (88%)
Lung 71 6.16± 11.46 (51%) 5.89± 11.85 (59%)
Skin 6 4.75 3.35 (67%) 4.33 3.27 (83%)
Oesophagus 16 3.41 ± 5.35 (25%) 3.31 ± 6.51 (38%)
Maxillary sinus 15 3.69 3.05 (47%) 3.91 ± 3.71 (47%)
Larynx 11 2.09± 1.31 (18%) 1.56± 1.56 (36%)
Oral cavity 14 2.38 2.04 (36%) 1.95 2.44 (36%)
Tongue 13 2.03± 1.39 (15%) 1.48± 1.32 (46%)
Pharynx 11 1.95± 0.85 (9%) 1.48± 1.32 (27%)
Serum TA-4 levels are represented as mean s.d. Numbers in parentheses are the
percentages of patients with TA-4 levels higher than the normal range.
Table II Serum TA-4 levels in patients with squamous cell
carcinoma of the lung determined by the conventional RIA method
and new IRMA method in relation to the clinical stages
Stage n Conventional RIA New IRMA
I 15 1.91 0.73 (27%) 1.23 0.77 (27%)
II 16 2.57± 1.83 (31%) 2.05± 1.96 (44%)
III 25 8.76 15.14 (60%) 8.27 14.23 (72%)
IV 15 9.91 ± 14.09 (73%) 10.64 16.62 (80%)
Serum TA-4 levels are represented as mean ± s.d. Numbers in
parentheses are the percentages of patients with TA-4 levels higher
than the normal range.
Discussion
It has been demonstrated that TA-4 is a relatively specific
marker of SCC and that its serum determination is useful for
diagnosis of SCC of various organs. The positive ratios
assessed as the percentage of patients with serum TA-4
higher than the normal range were, for example, 75% and
59% in SCC of the uterus and the lung, respectively. How-
ever, as reported previously (Mino et al., 1988), its diagnostic
usefulness seemed rather limited in SCC of other organs,
such as the oesophagus, head and neck. This was confirmed
in the present study when the conventional RIA method was
used for the assay of TA-4: the positive ratio was less than
50% in SCC of the oesophagus, head and neck (Table I). In
addition, even in SCC of the lung, the positive ratio was low
in the early stages of the disease (Mino et al., 1988) (see also
Table II). The major finding in the present study is that the
limitation of the diagnostic usefulness could be considerably
overcome by using the new assay method of IRMA. With the
IRMA method, the positive ratio was higher in SCC of
almost all organs including the uterus and lung (Table I). In
particular, the positive ratios with the IRMA method were
2-3 times higher than those with the RIA method in SCC of
the larynx, tongue and pharynx, while there were no
differences between the positive ratios with the two assay
methods in normal controls and in patients with benign
diseases or lung cancer other than SCC (Table I). Thus, the
sensitivity and accuracy of diagnosis of SCC was much im-
proved with the new assay method. These improvements may
be primarily ascribed to the use of two monoclonal
antibodies.
Previously, Kato et al. (1984) reported that TA-4 can be
roughly divided into two subgroups with an isoelectric focus-
ing method: one of acidic TA-4 with pl lower than 6.25 and
the other of neutral TA-4 with pl of 6.25 or higher. Further-
more, they demonstrated that TA-4 in the serum of healthy
controls is for the most part the neutral form, whereas TA-4
in the serum of patients with SCC is mainly the acidic form.
The antibodies used in the present IRMA method are more
specific for the acidic TA-4 than the polyclonal antibodies
used in the conventional RIA kit (Ikeda, 1987). In fact, the
TA-4 level in samples rich in acidic TA-4 is higher when
measured with the new IRMA tian that with the conven-
tional RIA (Ikeda, 1987). These differences in the specificity
of antibodies used may contribute to the improvement of the
diagnostic detectability of TA-4 mentioned above.
Additionally, the new IRMA method is a so-called sand-
wich method consisting of two antibodies: one labelled with
1251 and the other immobilised on polystyrene beads. It is
generally known that the sandwich method is superior to the
competitive RIA method in its sensitivity and accuracy (Ehr-
lich & Moyle, 1983). Indeed, lower intra- and interassay
deviations were obtained with this new IRMA method. Fur-
thermore, the lower limit of detection in the new method was
0.3 ng ml-', which was half the value obtained in the conven-
tional method. Thus, the new IRMA method must make it
possible to assay TA-4 more precisely, especially in samples
with very low TA-4 levels. In fact, the IRMA method gave
lower values than the RIA method in samples from SCC of
the oesophagus, head and neck, where TA-4 levels were
relatively low (Table I). Evidently, the improved accuracy of
this assay also contributes to the higher positive ratio in SCC
of these organs.
As evidenced in this study, the improved sensitivity and
accuracy afforded by the IRMA method has great diagnostic
significance. It should be stressed again that, by using two
monoclonal antibodies which are more specific compared
with a polyclonal antibody, the IRMA method enhances the
detectability of serum TA-4 in SCC of all organs.
We are grateful to Mrs Mariko Ata for her technical assistance.
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